Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Substance Use Disorders in HIV People of Cameroon

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02356185
Recruitment Status : Unknown
Verified February 2015 by Jean Joel R. Bigna, Goulfey Health District Unit.
Recruitment status was:  Not yet recruiting
First Posted : February 5, 2015
Last Update Posted : February 18, 2015
Sponsor:
Collaborators:
Yaounde Central Hospital
Edéa Regional Hospital
University of Yaounde 1
New York University School of Medicine
Information provided by (Responsible Party):
Jean Joel R. Bigna, Goulfey Health District Unit

Brief Summary:

Background:

Data are scarce concerning injecting drug use (IDU) and alcohol consumption among HIV-infected people on highly active antiretroviral treatment (HAART) in Cameroon. The aim of this study is to determine the prevalence of alcohol consumption and IDU among HIV-infected people on HAART; to determine sociodemographic factors associated with alcohol abuse and IDU among people on HAART; and to determine impact of alcohol consumption and IDU on adherence to HAART.

Methods/Design:

The investigators will conduct a cross sectional study at the Yaoundé Central Hospital in Cameroon, from February to August 2015. Using a self-report questionnaire, the investigators will include at least 1,000 HIV-infected adults (18 years or more) on HAART for at least one month coming for HIV care. The investigators will exclude pregnant women. Data collection will include sociodemographic and economic profile, alcohol consumption using Alcohol Use Disorders Identification Test, injecting drug use, adherence to HAART using visual analog scale and self-rate report. The investigators will perform sub-analysis for sex group and area of habitation. A p value < 0.05 will be considered statistically significant.

Discussion:

There is a critical need of accurate estimates of the amplitude and the distribution of IDU and alcohol consumption among HIV-infected adults, in order to inform health policies maker for curbing burden of both injecting drug use and alcohol consumption among people living with HIV.


Condition or disease
HIV

  Show Detailed Description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1000 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Prevalence, Socio-demographic Correlates of Substance Use Disorders Among HIV-infected Adults in Cameroon, and Their Influence on Adherence to Antiretroviral Therapy and Immunological Feature: Study Protocol for a Retrospective Cohort Study
Study Start Date : September 2015
Estimated Primary Completion Date : December 2015
Estimated Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS




Primary Outcome Measures :
  1. Adherence to antiretroviral therapy [ Time Frame: All days up to 180 days ]
    The investigators will measure adherence to antiretroviral therapy using a linear visual analogue scale on the past month as primary method of measure


Secondary Outcome Measures :
  1. Self-rate of adherence to antiretroviral therapy [ Time Frame: All days up to 180 days ]
    The investigators will measure adherence to antiretroviral therapy using self-rate by following scale: '1 - very good' to '5 - very bad'


Other Outcome Measures:
  1. Alcohol consumption [ Time Frame: All days up to 180 days ]
    The investigators will use the Alcohol Use Disorders Identification Test (AUDIT) to identify subjects with at-risk, hazardous, or harmful drinking. AUDIT has a possible range from 0 to 40. A score ≤ 7 is classified as no current problem (low risk drinking), a score range between 8 - 15 is classified as probable current problem drinking (risky or hazardous drinking), a score range between 16 - 19 is classified as high risk or harmful drinking, and a score ≥ 20 as define harm and likely to be alcohol dependent. The investigators prefer to use self-reported questionnaire vs. interview questionnaire because it may produce more accurate answers, but patients who will not well understand a question, could ask more clarifications. The investigators will therefore use AUDIT screening instrument test to classify current drinkers as problem or non-problem drinkers at cut-off ≥ 8.

  2. Injecting drug use [ Time Frame: All days up to 180 days ]
    Patients will report if Yes or No, they have already used an injectable drug. If yes, they will give frequency and last time of use.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
HIV infected people
Criteria

Inclusion Criteria:

  • aged 18 years or older
  • being for at least one month on highly active antiretroviral therapy

Exclusion Criteria:

  • pregnant women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02356185


Contacts
Layout table for location contacts
Contact: Jean Joel R Bigna, MD +237697224938 bignarimjj@yahoo.fr

Sponsors and Collaborators
Goulfey Health District Unit
Yaounde Central Hospital
Edéa Regional Hospital
University of Yaounde 1
New York University School of Medicine
Investigators
Layout table for investigator information
Principal Investigator: Jean Joel R Bigna, MD Goulfey Health District Unit

Additional Information:
Publications:

Layout table for additonal information
Responsible Party: Jean Joel R. Bigna, Head Officer, Goulfey Health District Unit
ClinicalTrials.gov Identifier: NCT02356185     History of Changes
Other Study ID Numbers: ASSIST-HIV
First Posted: February 5, 2015    Key Record Dates
Last Update Posted: February 18, 2015
Last Verified: February 2015

Keywords provided by Jean Joel R. Bigna, Goulfey Health District Unit:
Alcohol Drinking
Injecting drug
Antiretroviral therapy
sub-Saharan Africa

Additional relevant MeSH terms:
Layout table for MeSH terms
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders